60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
60 Degrees Pharma filed an 8-K on June 11th, likely with financial updates. Check for details.
AI Summary
On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that 60 Degrees Pharmaceuticals, Inc. has made a significant disclosure to the SEC, potentially impacting investor understanding of the company's current status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements,' with no immediate indication of negative news or significant financial distress in the provided text.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- June 11, 2024 (date) — Date of earliest event reported
- 001-41719 (other) — Commission File Number
- 45-2406880 (other) — IRS Employer Identification Number
- 1025 Connecticut Avenue NW Suite 1000 (address) — Registrant's principal executive office
- Washington, D.C. 20036 (address) — Registrant's principal executive office
FAQ
What specific "Other Events" are being reported by 60 Degrees Pharmaceuticals, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not detail the specific 'Other Events' being reported, only that this item is included.
What is the significance of the filing date and the date of the earliest event reported?
The filing date is June 12, 2024, and the date of the earliest event reported is June 11, 2024, indicating the company is reporting events that occurred on or before June 11th.
What is the Commission File Number for 60 Degrees Pharmaceuticals, Inc.?
The Commission File Number for 60 Degrees Pharmaceuticals, Inc. is 001-41719.
Where are the principal executive offices of 60 Degrees Pharmaceuticals, Inc. located?
The principal executive offices of 60 Degrees Pharmaceuticals, Inc. are located at 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036.
What is the Standard Industrial Classification (SIC) code for 60 Degrees Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for 60 Degrees Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-06-12 17:26:43
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
Filing Documents
- ea020775201-8k_60degrees.htm (8-K) — 31KB
- ea020775201ex99-1_60degrees.htm (EX-99.1) — 28KB
- image_002.jpg (GRAPHIC) — 6KB
- 0001213900-24-052167.txt ( ) — 291KB
- sxtp-20240611.xsd (EX-101.SCH) — 4KB
- sxtp-20240611_def.xml (EX-101.DEF) — 26KB
- sxtp-20240611_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240611_pre.xml (EX-101.PRE) — 25KB
- ea020775201-8k_60degrees_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On June 11, 2024, 60 Degrees Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company received U.S. Food and Drug Administration orphan drug designation for tafenoquine for treatment of patients with acute babesiosis. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of June 11, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: June 12, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President